Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q7L5N1
UPID:
CSN6_HUMAN
Alternative names:
JAB1-containing signalosome subunit 6; MOV34 homolog; Vpr-interacting protein
Alternative UPACC:
Q7L5N1; A4D2A3; O15387
Background:
COP9 signalosome complex subunit 6 (CSN6), also known as JAB1-containing signalosome subunit 6, MOV34 homolog, and Vpr-interacting protein, plays a pivotal role in cellular and developmental processes. It is a crucial component of the COP9 signalosome complex (CSN), regulating the ubiquitin conjugation pathway by deneddylation of cullin subunits of SCF-type E3 ligase complexes. This action decreases the ubiquitin ligase activity of complexes like SCF, CSA, or DDB2. CSN6 is involved in the phosphorylation of key proteins such as p53/TP53, c-jun/JUN, and others, potentially through its association with CK2 and PKD kinases. It also exhibits glucocorticoid receptor-responsive activity and stabilizes COP1, influencing the ubiquitination of COP1 targets.
Therapeutic significance:
Understanding the role of COP9 signalosome complex subunit 6 could open doors to potential therapeutic strategies.